Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Oct 5:3:1215848.
doi: 10.3389/fopht.2023.1215848. eCollection 2023.

Use of allogeneic platelet-rich plasma for the treatment of autoimmune ocular surface disorders: case series

Maura Mancini  1 , Elisa Imelde Postorino  1 , Ludovica Gargiulo  1 , Pasquale Aragona  1
Affiliations

Use of allogeneic platelet-rich plasma for the treatment of autoimmune ocular surface disorders: case series

Maura Mancini et al. Front Ophthalmol (Lausanne). .

Abstract

Purpose: To assess the effectiveness of topical allogeneic platelet-rich plasma (PRP) eye drops for the treatment of symptoms and clinical signs in patients with severe dry eye disease as a secondary condition caused by Sjögren's syndrome (SS).

Design: Case series and literature review.

Methods: Six eyes from three consecutive patients with severe dry eye from SS were evaluated. The eyes were treated with allogeneic topical PRP eye drops, with one drop applied six times daily for 3 months. A post-treatment follow-up evaluation was conducted 3 months after treatment suspension. We evaluated subjective symptoms, visual acuity, tear breakup time, the results of Schirmer's I test, fluorescein corneal and conjunctival staining, and corneal sensitivity.

Results: The symptoms and visual acuity improved significantly in all patients. There was a significant improvement in corneal sensitivity and a decrease or disappearance of fluorescein corneal staining.

Conclusion: The treatment with allogenic PRP eye drops of patients with SS-related severe dry eye disease has proven to be very effective, with an improvement in symptoms and main clinical signs.

Keywords: Sjogren’s syndrome; allogeneic platelet rich plasma; autoimmune ocular surface disorders; dry eye disease (DED); growth factors.

PubMed Disclaimer

Conflict of interest statement

PA is a consultant for the following companies: AbbVie, Alcon, Bausch + Lomb, DMG, FB Vision, Fidia Farmaceutici S.p.A., Medivis, Santen Pharmaceutical Co., Ltd., SIFI, and Théa. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Case 1: effect of the treatment with platelet-rich plasma eye drops on non-healing persistent epithelial defects (PEDs). (A) right eye before treatment; (B) left eye before treatment; (C) right eye after 3 months of treatment; and (D) left eye after 3 months of treatment.
Figure 2
Figure 2
Case 2: effect of the treatment with platelet-rich plasma eye drops on non-healing persistent epithelial defects (PEDs) in a patient who previously underwent radial keratotomy. (A) right eye before treatment; (B) left eye before treatment; (C) right eye after 3 months of treatment; and (D) left eye after 3 months of treatment.
Figure 3
Figure 3
Case 3: effect of the treatment with platelet-rich plasma eye drops on non-healing persistent epithelial defects (PEDs). (A) right eye before treatment; (B) left eye before treatment; (C) right eye after 3 months of treatment; and (D) left eye after 3 months of treatment.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Akpek EK, Klimava A, Thorne JE, Don M, Kaevalin L, Ann O. Evaluation of patients with dry eye for presence of underlying Sjögren syndrome. Cornea (2009) 28(5):493–7. doi: 10.1097/ICO.0b013e31818d3846 - DOI - PMC - PubMed
    1. Kassan SS, Moutsopoulos HM. Clinical manifestations and early diagnosis of Sjogren syndrome. Arch Intern Med (2004) 164(12):1275–84. doi: 10.1001/archinte.164.12.1275 - DOI - PubMed
    1. Bernabei F, Roda M, Buzzi M, Pellegrini M, Giannaccare G, Versura P. Blood- based treatments for severe dry eye disease: the need of a consensus. J Clin Med (2019) 8(9):1478. doi: 10.3390/jcm8091478 - DOI - PMC - PubMed
    1. Ralph RA, Doane MG, Dohlman CH. Clinical experience with a mobile ocular perfusion pump. Arch Ophtalmolol. (1975) 93(10):1039–43. doi: 10.1001/archopht.1975.01010020815015 - DOI - PubMed
    1. Fox RI, Chan R, Michelson JB, Belmont JB, Michelson PE. Beneficial effect of artificial tears made with autologous serum in patients with keratoconjunctivitis sicca. Arthritis Rheumatol (1984) 27:459–61. doi: 10.1002/art.1780270415 - DOI - PubMed

LinkOut - more resources